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Abstract
 
The adaptor protein Lnk, and the closely related proteins APS and SH2B, form a subfamily of
SH2 domain-containing proteins implicated in growth factor, cytokine, and immunoreceptor
signaling. To elucidate the physiological function of Lnk, we derived 
 
Lnk
 
-deficient mice.
 
Lnk
 
 
 
/
 
 
 
 mice are viable, but display marked changes in the hematopoietic compartment, in-
cluding splenomegaly and abnormal lymphoid and myeloid homeostasis. The in vitro prolifer-
ative capacity and absolute numbers of hematopoietic progenitors from 
 
Lnk
 
 
 
/
 
 
 
 mice are
greatly increased, in part due to hypersensitivity to several cytokines. Moreover, an increased
synergy between stem cell factor and either interleukin (IL)-3 or IL-7 was observed in 
 
Lnk
 
 
 
/
 
 
 
cells. Furthermore, 
 
Lnk
 
 inactivation causes abnormal modulation of IL-3 and stem cell factor–
mediated signaling pathways. Consistent with these results, we also show that Lnk is highly ex-
pressed in multipotent cells and committed precursors in the erythroid, megakaryocyte, and
myeloid lineages. These data implicate Lnk as playing an important role in hematopoiesis and
in the regulation of growth factor and cytokine receptor–mediated signaling.
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Introduction
 
The growth, differentiation, and function of immune and
hematopoietic cells are controlled by the coordinated ac-
tions of multiple cytokines (1). Members of the cytokine
receptor superfamily function through their association
with one or more members of the Janus (JAK)
 
*
 
 family of
cytoplasmic tyrosine kinases (2, 3). Cytokines induce oligo-
merization of their receptors, followed by transphosphory-
lation and activation of the JAK kinases. The activated
JAKs phosphorylate tyrosine residues in the receptor and
subsequently downstream substrates, such as the signal
transducers and activators of transcription (STAT) proteins
(4). Once recruited to the receptor complex, STAT pro-
teins are themselves phosphorylated on tyrosine, and
dimerize and translocate into the nucleus, where they acti-
vate the transcription of genes mediating cytokine-induced
responses. The JAK/STAT pathway is tightly regulated,
and deregulated JAK or STAT activity has been implicated
in several hematopoietic disorders, autoimmunity, inflamma-
tory diseases, and in cell transformation (5–8).
Cytokines also activate other signaling cascades, such as
the Ras/mitogen-activated protein kinase (MAPK) and the
phosphoinositide 3-kinase (PI3K)/Akt pathways (9–11).
These have been implicated in the proliferation, survival,
and differentiation of several cell types in the hematopoietic
system (12–14). Indeed, deregulation of these pathways has
been implicated in the pathogenesis of hematopoietic dis-
eases (15–18).
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Role of Lnk in Hematopoietic Cells
 
Lnk was originally identified as a 38-kD adaptor protein
expressed mainly in hematopoietic tissues (19, 20). How-
ever, it was later found that the Lnk protein is much larger
than initially reported (21, 22, and this work). The full-
length mouse Lnk protein contains an NH
 
2
 
-terminal pro-
line rich region, a pleckstrin homology (PH) domain, a Src
homology 2 (SH2) domain, and potential tyrosine phos-
phorylation sites. Lnk, and the closely related proteins APS
and SH2-B, form a subfamily of SH2-containing proteins
with potential adaptor functions (23, 24). Members of the
Lnk family are expressed in a wide variety of tissues, and
therefore, may be involved in diverse signaling pathways.
Indeed, APS and SH2-B have been shown to be phos-
phorylated after stimulation of growth factor (23, 25–30),
cytokine (23–33), and immunoreceptors (21, 23, 24). SH2-
B
 
 
 
 (an isoform of SH2-B) and APS are substrates of the
Trk family of neurotrophin receptors, and positive media-
tors of nerve growth factor signaling in PC12 cells (27).
SH2-B is also an activator of JAK2 in response to growth
hormone (34), whereas APS appears to be a negative regu-
lator of JAK2 after erythropoietin (EPO) stimulation (32)
and inhibits platelet-derived growth factor–induced mito-
genesis (35). These observations suggest that these adaptor
proteins are regulators of growth factor and cytokine re-
ceptor–mediated pathways.
Despite substantial data implicating this new family of
adaptor proteins in signaling, their physiological roles in
hematopoietic cell signaling have not been defined. How-
ever, Takaki et al. (22) have demonstrated that 
 
Lnk
 
-defi-
cient mice display defects in B lymphopoiesis. We have
also generated 
 
Lnk
 
-deficient mice and have also observed
an effect on B cell production and function. In addition,
we demonstrate here that 
 
Lnk
 
 
 
/
 
 
 
 mice display spleno-
megaly, hyperplasia of the megakaryocytic lineages, and in-
creased numbers of both erythroid cells in the spleen and
hematopoietic progenitors. Consistent with this, we show
that Lnk is highly expressed in multipotent cells and pre-
cursors of hematopoietic lineages. Moreover, 
 
Lnk
 
 
 
/
 
 
 
 cells
show an increased sensitivity to several cytokines and al-
tered activation of the Ras/MAPK pathway in response to
IL-3 and stem cell factor (SCF). These results demonstrate
that Lnk regulates proliferation of several hematopoietic
cell lineages and suggest that it is an important component
of growth factor and cytokine signal transduction in he-
matopoietic cells.
 
Materials and Methods
 
Generation of Lnk-deficient Mice.
 
A 129/Sv mouse genomic li-
brary (Stratagene) was screened with a rat 
 
Lnk
 
 cDNA probe.
Exon/intron boundaries were determined by restriction enzyme
mapping, DNA sequencing, and PCR. To generate the targeting
construct, a 5-kb SacI fragment containing 5
 
 
 
 
 
Lnk
 
 genomic DNA
and a 2-kb SacI fragment containing 3
 
 
 
 sequence were cloned
into pPNT. The targeting construct was linearized with NotI and
electroporated into RI embryonic stem (ES) cells, and transfec-
tants were selected as described previously (36, 37). Aggregation
chimeras were generated with targeted ES cells, and chimeric
 
males were mated with 129/Sv females and germline transmission
of the mutated allele was verified by PCR analysis of tail DNA
from F1 mice. Heterozygous offspring were intercrossed to gen-
erate homozygous mutants. No differences in phenotype were
observed between 
 
Lnk
 
 mutant mice from different genetic back-
grounds (129/Sv or C57BL/6).
Poly(A)
 
 
 
 RNA from E13.5 embryos from each genotype was
purified once on an oligo-(dT) column. 2 
 
 
 
g of poly(A)
 
 
 
 RNA
was fractionated in a 1% agarose gel containing 2.2 M formalde-
hyde, and transferred to a Hybond-N membrane (Amersham
Pharmacia Biotech). Hybridization was performed in Church
buffer (500 mM phosphate buffer, pH 6.8, and 7% SDS) at 65
 
 
 
C
overnight. A 500-bp NH
 
2
 
-terminal 
 
Lnk
 
 cDNA fragment was
used as a probe. The membrane was washed in 0.1
 
 
 
 SSC, 0.1%
SDS at 65
 
 
 
C. The Northern blot was stripped by boiling for 5
min in 0.1% SDS, 0.1
 
 
 
 SSC, and 0.05% sodium pyrophosphate.
RNA loading was evaluated by hybridization with a 1.4-kb glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) probe.
 
Immunohistochemistry and Peripheral Blood Analysis.
 
Mouse tis-
sues were fixed in 10% buffered formalin, paraffin embedded,
sectioned, and stained with hematoxylin and eosin. For immuno-
histochemical analysis, spleens were embedded in OCT com-
pound (Tissue-Tek Sakura), snap frozen in dry ice, and stored at
 
 
 
70
 
 
 
C. Cryostat sections (8–10 
 
 
 
m thick) were dried overnight
and fixed with acetone. Slides were rehydrated and preincubated
for 1 h in staining buffer (1
 
 
 
 PBS and 0.1% NP-40) containing
5% heat-inactivated rat serum. Sections were incubated with
FITC- or phycoerythrin (PE)-conjugated primary antibodies (BD
PharMingen) in a humidified chamber for 1 h at room tempera-
ture. After three washes in staining buffer and one wash in 1
 
 
 
PBS, the slides were mounted in 
 
p
 
-phenylenediamine (Sigma-Al-
drich) in PBS and glycerol (50% vol/vol) to retard photobleach-
ing. The antibodies used for immunohistochemistry were PE–
anti-B220, PE–anti-Ter119, and FITC–anti-CD41. Visual data
were acquired with a fluorescent microscope (Leica).
Peripheral blood analysis was performed on a blood analyzer
(Coulter electronics). Peripheral blood smears were stained with
Wright-Giemsa (Fisher) and scored microscopically based on
morphology.
 
Flow Cytometric Analysis.
 
Bone marrow and spleen cells ob-
tained from wild-type or mutant mice were made into single
cell suspensions in staining buffer (cold PBS supplemented with
2% FBS). The cells were stained on ice for 30 min with FITC,
PE, APC, or biotin-conjugated mAbs. The stained cells were
washed twice in staining buffer and analyzed using a FACScan
 
TM
 
flow cytometer and CellQuest
 
TM
 
 software (Becton Dickinson).
The following mAbs were used: PE, APC, or biotin–anti-B220,
PE–anti-Ter119, PE–anti-Mac-1, PE–anti-CD43, PE–anti-
CD22, PE–anti-CD23, FITC–anti-CD41, FITC–anti-Gr-1,
FITC–anti-BP.1, and biotin–anti-HSA; all were purchased from
BD PharMingen. FITC–anti-IgM is the clone 33.60 (38).
Biotin-stained cells were labeled with Quantum red (Sigma-
Aldrich).
 
B Cell Proliferation Assays.
 
To obtain enriched B cell popula-
tions, splenocytes from wild-type and mutant mice were treated
with ACK (0.155 M ammonium chloride, 0.1 mM disodium
EDTA, and 0.01 M potassium bicarbonate) for red cell lysis fol-
lowed by T cell depletion. Cells were incubated with anti-
Thy1.2 antibody (clone H013.4.9), anti-CD4 (clone RL172.4H),
and anti-CD8 (clone 3.168) supernatants and low tox guinea pig
complement (Cedarlane Laboratories). The resulting enriched
splenic B cells were cultured at 10
 
5
 
 cells/well in flat-bottom 96-
well plates in OPTI-MEM (GIBCO BRL) medium 
 
 
 
 5% FBS 
1601
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and with or without 100 ng/ml IL-7, 50 ng/ml SCF (Pepro-
Tech), IL-7 and SCF, 10 
 
 
 
g/ml LPS, and 10 
 
 
 
g/ml anti-IgM for
2–6 d. The cultures were pulsed with 1 
 
 
 
Ci/well [
 
3
 
H]thymidine
for 6 h and harvested. Incorporated radioactivity was determined
by a Betaplate Counter (Packard Instrument Co.). IL-7 was ob-
tained from the supernatant of the stably transfected J558 line (Dr.
A Cumano, Institute Pasteur, Paris, France). For the proliferation
assay of CD43
 
 
 
 pro-B cells, bone marrow cells were enriched
and prepared as described previously (39).
 
In Vitro Bone Marrow and Spleen Cultures.
 
For liquid cultures,
single cell suspensions of bone marrow and spleen cells were pre-
pared in IMDM (GIBCO BRL) supplemented with 15% heat-
inactivated FBS, 50 
 
 
 
M B-mercaptoethanol, antibiotics, 200
 
 
 
g/ml transferrin (Sigma-Aldrich), 10 
 
 
 
g/ml insulin (Boe-
hringer), and 1% BSA. Cells were plated in 96-well tissue culture
plates at 10
 
4
 
 (for bone marrow) or 5 
 
 
 
 10
 
4
 
 cells/well (for spleen)
in various concentrations of recombinant murine IL-3 (Pepro-
Tech), SCF (PeproTech), or IL-3 and SCF. After 4–6 d in cul-
ture, cells were stained with MTT (3-[4,5-dimethyl thiazol-
2-yl]-2,5-diphenyl tetrazolium bromide) as suggested by the
manufacturer (Boehringer).
 
In Vitro Hematopoietic Progenitor Colony Assays.
 
Single cell sus-
pensions were prepared from bone marrow aspirates or spleen
under sterile conditions. Triplicate samples of 10
 
4
 
 or 10
 
5
 
 cells
(for CFU-GEMM) were plated in methylcellulose (MethoCult
M3434) containing cytokines, including erythropoietin (Stem
Cell Technologies Inc.), and incubated at 37
 
 
 
C, 5% CO
 
2
 
, 100%
humidity. Progenitor colony-forming units were counted at 2 d
(CFU-E), 8 d (BFU-E), and 10 d (CFU-GM, CFU-GEMM) af-
ter benzidine staining. Megakaryocyte progenitors (2 
 
 
 
 10
 
4
 
 cells)
were assayed in collagen-based media (MegaCult-C; Stem Cell
Technologies Inc.). Colonies were stained for acetylcholines-
terase activity and counted after 6 d incubation. Bone marrow
pre-B cell progenitors (5 
 
 
 
 10
 
4
 
 cells) were detected by culture in
methylcellulose media (MethoCult M3231; Stem Cell Technolo-
gies Inc.) supplemented with IL-7 (10 ng/ml; BD PharMingen)
or IL-7 and SCF (50 ng/ml; PeproTech). Colonies were scored
microscopically after 7 d.
 
Immunoprecipitation and Western Blot Analysis.
 
Polyclonal rabbit
antisera was raised against an NH
 
2
 
-terminal synthetic peptide
(amino acid 72–91) of mouse Lnk. Spleens and testis from wild-
type, heterozygous, and homozygous mice were homogenized
and lysed in ice-cold lysis buffer (1% Triton X-100, 150 mM
NaCl, 50 mM Tris-HCl, pH 7.6, 1 mM EDTA, 10% glycerol, 1
mM Na
 
3
 
VO
 
4
 
, 10 mM NaF, 1 mM PMSF, 10 
 
 
 
g/ml aprotinin,
and 10 
 
 
 
g/ml leupeptin). Immunoprecipitations were done with
anti-Lnk–NH
 
2
 
-terminal antibodies and separated on a 8–12%
SDS-PAGE gradient gel. Western blot analysis was performed
with anti-Lnk–NH
 
2
 
-terminal antibodies, followed by incubation
with HRP-conjugated protein A (Bio-Rad Laboratories) and de-
tection via ECL reagents (Pierce Chemical Co.).
 
Preparation of Bone Marrow–derived Mast Cells and In Vitro Cul-
tures.
 
Primary cultures of IL-3–dependent bone marrow–
derived mast cells (BMMCs) from 6–8-wk-old wild-type and
mutant mice were prepared and maintained as described previ-
ously (40). For MAPK analysis, BMMCs were plated in starving
media (IMDM: 0.5% FBS and 1% BSA, pH 7) for 16 h and stim-
ulated with 100 ng/ml SCF (PeproTech) or 100 ng/ml IL-3 (BD
PharMingen) for the indicated times at 37
 
 
 
C. Cells were then
washed once with ice-cold PBS containing 1 mM Na
 
3
 
VO
 
4
 
, and
lysed in ice-cold lysis buffer for 30 min on ice. Lysates were
cleared by centrifugation at 13,000 rpm for 10 min, and superna-
tants containing the whole cell lysates were analyzed on SDS-
 
PAGE gels. Proteins were transferred to nitrocellulose mem-
branes (Schleicher & Schuell) and immunoblotted with mono-
clonal antiphosphotyrosine 4G10 (UBI), phospho-specific Akt,
or phospho-specific ERK1/2 MAPK (both from New England
Biolabs, Inc.) antibodies. To verify equivalent loading and to
confirm the identity of phosphorylated MAPK and Kit receptor,
membranes were stripped as recommended (ECL; Amersham
Pharmacia Biotech) and then blotted with anti-ERK1 and ERK2
(0.5 
 
 
 
g/ml each; Santa Cruz Biotechnology, Inc. and UBI, re-
spectively) or anti-Kit (40) antibodies. Immunoprecipitation and
Western blot analysis of IL-3 receptor
 
 
 
 
 
 
 
chain
 
 (
 
IL-3R
 
 
 
) were
done as described previously (41). Immunoblots were visualized
with enhanced chemiluminescence detection reagents (ECL;
Amersham Pharmacia Biotech). Densitometric scanning was per-
formed with a high resolution Fluor-S Max
 
TM
 
 multilmager (Bio-
Rad Laboratories).
 
BMMC In Vitro Proliferation Assay.
 
For in vitro proliferation
assays, BMMCs in IMDM complete medium were starved of
IL-3 for 12 h; 5 
 
 
 
 10
 
4
 
 cells were seeded in triplicate in 96-well
plates and stimulated with the indicated concentrations of SCF or
IL-3 for 28 h. After 20 h, 1 
 
 
 
Ci/well of [
 
3
 
H]thymidine was added
for 12 h. Cells were harvested and [
 
3
 
H]thymidine incorporation
was measured by a Betaplate counter (Packard Instrument Co.).
 
Expression Analysis.
 
A Slot blot containing amplified cDNAs
from various hematopoietic cells ranging from pentapotent pre-
cursors to terminally mature cells in erythroid, myeloid, and lym-
phoid lineages, or different organs (a gift from Norman N. Is-
cove, Ontario Cancer Institute) was hybridized as described
previously (42). A 350-bp fragment containing the terminal 3
 
 
 
untranslated (close to the polyadenylation site) sequence of 
 
Lnk
 
was used as a probe. L32, a constitutively expressed “housekeep-
ing” transcript encoding a ribosomal subunit protein, was used as
a probe to confirm equal loading of cDNAs samples.
 
Results
 
Disruption of the Lnk Gene and Generation of Lnk
 
 
 
/
 
 
 
Mice.
 
To address the biological function of 
 
Lnk in vivo,
we generated mice carrying a germline mutation in Lnk by
homologous recombination in RI mouse ES cells. A tar-
geting vector was designed to replace a 1.6-kb DNA frag-
ment containing exons II–VII of Lnk with a PGK-neomy-
cin cassette (Fig. 1 A). The deleted exons encoded the
originally reported coding sequence of Lnk (19). Success-
ful homologous recombination and germline transmission
was confirmed by Southern blot and PCR analysis of ES
cells and tail-derived genomic DNA (from offspring of
heterozygous parents), respectively (Fig. 1, B and C).
Northern and Western blot analyses of different tissue ex-
tracts derived from mice of each genotype were performed
with a 500-bp NH2-terminal Lnk probe (exon 1) or anti-
bodies raised against the NH2-terminal region of the Lnk
protein, respectively (Fig. 1, D and E). This analysis con-
firmed the absence of Lnk-specific protein products in the
Lnk-deficient mice.
Lnk /  Mice Exhibit Extramedullary Hematopoiesis. Ho-
mozygous Lnk /  mice were present at the expected Men-
delian ratio of 1:2:1 (n   330) from intercrosses of het-
erozygous parents. Both Lnk /  female and male animals
were viable and fertile, with normal longevity.1602 Role of Lnk in Hematopoietic Cells
We performed a histological analysis of neonatal and
adult mice to identify tissue abnormalities in Lnk-deficient
animals. This identified a severe splenic disorder in Lnk / 
mice characterized by splenomegaly (weight, 0.062  
0.015 g for  /  mice compared with 0.195  0.07 g for
 /  mice; P   0.01; Fig. 2 A), fibrosis, and extensive ex-
tramedullary hematopoiesis (EMH), in which increased
numbers of megakaryocytes (CD41  cells) and erythro-
cytes (Ter119  cells) were apparent in the splenic red pulp
(Fig. 2, C, F, and G). This increased EMH in the spleen of
mutant mice was apparent from birth (unpublished data).
In general, the architecture of the spleen was considerably
changed in the Lnk-deficient mice. The white pulp, with
its characteristic discrete lymphoid follicles (Fig. 2 B), pre-
sented dramatic changes in shape (Fig. 2 C), accompa-
nied by an increase in B220  lymphocytes (Fig. 2, D and
E). The bone marrow histology of Lnk mutant mice re-
vealed an increase in the number of megakaryocytes and a
slight decrease in erythroid cell number (unpublished data).
Lymph nodes were often enlarged in Lnk /  mice and
showed increased numbers of B cells (unpublished data).
No morphological differences between wild-type and Lnk-
deficient animals were observed in any other tissue, includ-
ing thymus, liver, kidney, and lungs. For all parameters an-
alyzed, the Lnk heterozygous mice showed an intermediate
phenotype between the wild-type and homozygous mutant
mice (Fig. 2 A and unpublished data). Together, these re-
sults revealed hyperplasia of the megakaryocytic, erythroid,
and B cell lineages in the spleen of Lnk /  mice with the
latter two contributing to increased cellularity in this organ
and splenomegaly.
Figure 1. Targeted disruption of the Lnk locus. (A) Structure of the
Lnk locus (top), targeting construct (middle), and predicted Lnk mutant
allele (bottom) is shown; 1 kb   0.5 cm. (B) Southern blot analysis of
EcoRV-digested ES cell-derived genomic DNA with a 3  external probe.
The wild-type (wt) fragment and the mutant (mut) allele are indicated.
(C) PCR analysis of tail-derived genomic DNA from F2 mice resulting
from a cross between two Lnk /  mice with both Lnk and neo-specific
primers. (D) Northern blot analysis of Lnk expression. 2  g
poly(A) RNA from E13.5 embryos was hybridized with an NH2-termi-
nal Lnk cDNA (top) or GAPDH probe (bottom). (E) Immunoprecipita-
tion and Western blot analysis of spleen and testis extracts from wild-type
( / ), heterozygous ( / ), and homozygous ( / ) Lnk mice. The
Lnk antibody used was raised against amino acid 72–91 of the Lnk pro-
tein. H, HindIII; X, XbaI; S, SacI; E47, EcoR47; B, BamHI; RV,
EcoRV; neo, neomycin resistance cassette; TK, thymidine kinase.
Figure 2. Primary splenomegaly and extramedullary hematopoiesis in
Lnk /  mice. (A) Gross anatomy of spleens from Lnk wild-type (top),  / 
(middle), and  /  (bottom) mice. (B and C) Low power magnification
(10 ) of hematoxylin and eosin staining of splenic sections from wild-
type (B) and Lnk /  (C) mice showing enlargement of the white (W) and
red (R) pulp. (D–G) Cryosections of spleens from wild-type (D and F) or
Lnk-deficient mice (E and G) were stained with anti-B220 (red, D and
E), anti-Ter119 (red, F and G), and anti-CD41 (green, F and G)–conju-
gated antibodies. Original magnification: 50  (D and E), 200  (F and G).1603 Velazquez et al.
Lnk /  Mice Exhibit Defects in Hematopoietic Homeosta-
sis. Based on these observations, we examined specific he-
matological parameters in the mutant mice. No significant
differences in peripheral red blood cell counts or in hemat-
ocrits were observed between wild-type and Lnk /  mice.
However, the white blood cell counts and circulating platelet
levels in Lnk mutants were markedly increased as compared
with wild-type mice. Differential counts of peripheral blood
smears revealed a substantial elevation in the numbers of cir-
culating lymphocytes, monocytes, and neutrophils (Table I).
Flow cytometric analysis (FACS) of bone marrow and
spleen cells was then performed to further characterize the
hematopoietic perturbations in the Lnk /  mice. The per-
centage of B220  lymphocytes was increased in the bone
marrow and in the spleen (8–13% above  /  littermates)
of Lnk-deficient mice (Table II). Similarly, the percentage of
cells positive for CD41, expressed on megakaryocytes, was
elevated in the bone marrow (twofold) and more dramati-
cally in the spleen (threefold) of Lnk /  mice (Table II). In
addition, the percentage of Ter-119–positive erythroid cells
in Lnk-deficient mice was decreased 36% in the bone mar-
row but increased twofold in the spleen of Lnk mutant mice
(Table II), which is consistent with the elevated splenic
erythropoiesis observed previously (Fig. 2 A). Finally, the
percentage of Gr-1/Mac-1  cells, representing monocyte/
granulocyte progenitors, was decreased 15% in the bone
marrow, but remained similar in the spleen of Lnk /  mice
(Table II). When combined with the increase in cellularity
in both the bone marrow and spleen compartments of Lnk / 
mice, these FACS data reveal a significant elevation of both
B lymphoid and megakaryocyte populations, as well as en-
hanced erythroid numbers in the spleen (Table II). The
FACS data are consistent with the changes observed in the
peripheral blood counts and with the histological findings in
bone marrow and spleen of Lnk-deficient mice.
Lnk /  Mice Have Altered Hematopoietic Progenitor Num-
bers. To determine if the perturbations in the hematopoi-
etic organs and peripheral blood arise at the progenitor level,
bone marrow and spleen cells from Lnk / , Lnk / , and
Lnk /  mice were grown in vitro in semi-solid media with
various growth factors to quantitate multilineage (CFU-
GEMM), pre-B, megakaryocytic (CFU-Meg), and eryth-
roid (BFU-E and CFU-E) progenitor cells (Fig. 3 A). The
absolute numbers of clonogenic progenitors observed with
Lnk /  cells were intermediate between wild-type and mu-
tant levels (unpublished data). The number of multilineage
colony-forming cells (CFU-GEMM) was significantly in-
creased in Lnk /  bone marrow (2.5-fold) and spleen (8-
Table I.  Hematological Parameters of Wild-type and
Lnk-deficient Mice
Parameter  / a  /  P valueb
Peripheral blood
WBC (106/ml) 7.6   1.5  26.6   6.04 **
RBC (106/ml) 8.4   0.9 7.8   0.7 NS
Hematocrit (%) 48   3.3   49   2N S
Platelets (106/ml)  400   107 1,903   219 **
Differential counts (106/ml)
Lymphocytes 6.44   1.39 22.12   5.55 **
Monocytes 0.130   0.05 0.420   0.102 **
Neutrophils 1.04   0.51 3.91   1.15 **
Eosinophils 0.106   0.07 0.394   0.22 *
WBC, white blood count; RBC, red blood count.
aValues represent the mean   SD for 10 animals per determination per
genotype. 
bStatistical significance was determined using the Student’s t test where
*, P   0.05; **, P   0.005; NS, not significant.
Table II. Cell Population in Wild-type and Lnk-deficient mice (in millions)
Total cells 
B cells
B220 
Erythroid
Ter119 
Megakaryocyte
CD41 
Myeloid
Gr-1/Mac-1 
No. % No. % No. % No. %
Bone marrow
Wild type 13   3.6 4.3   0.59 34.1   4.6 0.90   0.20 7.0   1.5 1.1   0.10 8.5   0.81 6.1   1.1 48   8.7
Lnk-deficient 14   1.2  6.6   0.71b 47.5   5.1 0.63   0.20 4.5   1.3 2.3   0.37c 17   2.6 5.0   0.66 33   4.7
Spleen
Wild type 63   15.4 32.1   5.4  51   8.6  2.2   0.98 3.5   1.6 4.0   0.11 6.0   0.17 1.5   0.30 12   2.3
Lnk-deficient 82   25d 49   3.1a  59   3.8  4.6   0.98b 6.0   1.2 15   1.4b 18   1.7 2.2   0.51c 13   3.2
The phenotype of each cell population was determined by flow cytometry. The numbers and percentage of each group of cells were determined for
each mouse for at least three to five mice per genotype, and the mean and SD were calculated. 
aP   0.001.
bP   0.005. 
cP   0.02.
dP   0.05.1604 Role of Lnk in Hematopoietic Cells
fold) compared with  /  littermates. Similarly, the num-
ber of pre-B lymphoid colony-forming cells in Lnk /  bone
marrow was increased two- and sevenfold relative to wild-
type mice in the presence of IL-7 or IL-7 and SCF, respec-
tively (Fig. 3 A). Although only slight differences were ob-
served in the number of precursors of small erythroid 2-d
colonies (CFU-E) and CFU-megakaryocyte (CFU-Meg) in
Lnk /  bone marrow, increased numbers of these colonies
were seen in cells derived from the spleen. A similar result
was observed with precursors of large erythroid-only 6–8-d
colonies (BFU-E) and granulocyte-macrophage (CFU-GM)
progenitor numbers (unpublished data).
Moreover, there was a marked difference in the prolifer-
ative capacity of Lnk /  progenitors. The pre-B lymphoid
and CFU-Meg colonies from bone marrow and spleen of
Lnk-deficient mice were typically three to five times larger
than the colonies derived from wild-type mice (Fig. 3 B).
We observed a similar effect on the colony size of CFU-
GEMM from Lnk /  mice. These results suggest that the
variations in differentiation potential observed are intrinsic
to the Lnk /  progenitor cells, and that these cells have an
enhanced responsiveness to cytokines.
Lnk /  Mice Are Affected in B Cell Maturation and Prolifer-
ation. Because there was an increase in the number of
B220  cells in the Lnk mutant mice, we examined which B
cell populations were affected by the lack of the Lnk pro-
tein. FACS analysis of bone marrow–derived B cells re-
vealed that wild-type and Lnk mutant mice display similar
percentages of pro-B (B220 CD43 ) cells (Fig. 4 A). Fur-
ther analysis of the pro-B compartment by four-color
FACS staining indicated that Lnk /  mice have an increase
in the percentage of BP.1 HSA  cells relative to wild-type
mice (Fig. 4 A). This population corresponds to the IL-7–
responsive, Fraction C stage of B cell development (43).
The increase in Fraction C cells is accompanied by a slight
decrease in the percentage of HSA BP.1 , Fraction B cells
(Fig. 4 A). A more profound increase is observed in the
pre-B cell population in Lnk-deficient animals, which can
be visualized by the B220 IgM  and B220 CD43 
populations shown in Fig. 4 A. Later stages of de-
velopment were also altered in the absence of Lnk expres-
sion. An accumulation of the immature population of
B220loCD43 IgM  cells and a decreased percentage of
more mature, recirculating B220hiIgM  cells were identi-
fied in Lnk-deficient mice (Fig. 4 A). In addition, a greater
proportion of the IgM  cells in the bone marrow and
spleen of Lnk /  mice expressed reduced levels of CD22
and CD23, which is consistent with the observed accumu-
lation of cells at the immature B cell stage of development
(Fig. 4, A and B). The differences in the proportion of B
cell precursors in wild-type and Lnk-deficient animals are
more pronounced when the increase in Lnk /  bone mar-
row cellularity is taken into account. This analysis also
reveals that the absolute number of recirculating cells is
similar to that found in control mice (1.5-fold increase,
compared with 3–4-fold increase in pro-, pre-, and imma-
ture B cells; unpublished data). Elevated numbers of imma-
ture IgM  B cells may arise after the maturation of the ex-
panded pre-B population present in Lnk /  mice, or may
indicate incomplete maturation past the B220loCD43 
IgM , Fraction E cell stage in the absence of Lnk expres-
sion. Support for the hypothesis of incomplete maturation
of the B cell lineage was found in the spleen, where the
presence of a high frequency of IL-7–responsive cells was
observed (1:100 in Lnk /  compared with 1:11,000 in
wild-type mice; unpublished data) in the absence of detect-
able numbers of IgM  B cell precursors (Fig. 4 B). To-
gether, these data indicate that an increase in B lineage cells
is evident as early as the IL-7–responsive, Fraction C stage
of development, and that an accumulation of cells at the
Figure 3. In vitro proliferative capacity of early hematopoietic progen-
itors in bone marrow and spleen cells from wild-type and Lnk mutant
mice. (A) In vitro colony-forming ability of bone marrow and spleen he-
matopoietic progenitors from wild-type and Lnk-deficient mice. The
mean and SD of the number of colonies/105 cells are shown from assays
using three mice of each genotype in triplicate. Statistical significance was
determined using the Student’s t test: *, P   0.05; **, P   0.02; ***, P  
0.01. (B) Typical appearance of pre-B (left) in IL-7   SCF and CFU-Meg
(center and right) colonies derived from wild-type and Lnk-deficient cells
after 7 d of incubation in methylcellulose media containing optimal con-
centrations of appropriate recombinant growth factors (Materials and
Methods). CFU-GEMM, colony-forming units of granulocyte, eryth-
roid, macrophage, and megakaryocyte cells; CFU-E, precursors of small
erythroid 2-d colonies; CFU-Meg, colony-forming units of megakaryo-
cyte cells; BM, bone marrow. Scale bar: pre-B colonies, 20  m; CFU-Meg
colonies, 200  m.1605 Velazquez et al.
B220lo, immature B cell stage occurs in the bone marrow
and spleen in Lnk-deficient mice.
To further assess the maturation state of B cell precursors
in the Lnk-deficient mice, we analyzed the ability of bone
marrow and splenic B cells to proliferate in response to var-
ious stimuli. CD43  pro-B cells were sorted from the bone
marrow and grown in a titration of IL-7. These culture
conditions permit the expansion of IL-7–responsive pro-B
cells, as well as their maturation to the pre-B cell receptor
(pBCR)–expressing pre-B stage. Recent reports have dem-
onstrated that a signal downstream of the pBCR is required
for proliferation in picogram concentrations of IL-7 (39).
As shown in Fig. 5 A, cells from both the Lnk /  and con-
trol mice are able to proliferate above background in low
concentrations of IL-7. A slight elevation in background
[3H]thymidine incorporation by Lnk-deficient cells is ob-
served in the absence of IL-7. However, these cells exhibit
a more significant twofold elevation in proliferation when
stimulated with picogram per milliliter concentrations of
IL-7. FACS staining revealed that cells from both geno-
Figure 4. FACS analysis of Lnk-deficient B cells. Bone marrow (A) or splenic (B)
cells from wild-type and Lnk-deficient mice were stained with the indicated conju-
gated antibodies. All panels represent lymphocyte-gated cells, with the exception of
BP.1/HSA four-color staining that is gated on lymphocytes and B220 CD43  cells.
Numbers indicate percentage of gated cells in the indicated boxes. Plots are representa-
tive of three sets of mice of each genotype.1606 Role of Lnk in Hematopoietic Cells
types matured to express CD2 in high and low concentra-
tions of IL-7 (unpublished data). The absence of a signifi-
cant increase in the proliferation of mutant precursors in
response to nanogram concentrations of IL-7 suggests that
the phenotype observed in reduced levels of IL-7 is not
due to the presence of a higher percentage of BP.1  cells in
the sorted population. Together, these results indicate that
Lnk expression may not be required to transmit pBCR sig-
nals at this stage in development, and suggest that the pre-B
cells have not fully matured and lost the ability to respond
to IL-7 (44). Similarly, splenic B cells from Lnk-deficient
mice showed a significant increase in proliferation after IL-7
stimulation (Fig. 5 B). This is consistent with the elevated
frequency of IL-7–responsive precursors detected in the
mutant spleen, and is indicative of a very immature pheno-
type extending to the periphery. In addition, the prolifera-
tion of Lnk-deficient splenic B cells is further enhanced by
concurrent stimulation with IL-7 and SCF (Fig. 5 B).
Splenic B cells were also assayed for proliferation after
BCR stimulation. Although Lnk-deficient cells maintain
the ability to proliferate in response to the mitogen LPS,
the response of splenic Lnk /  B cells to anti-IgM was par-
tially reduced at any of the time points examined (Fig. 5 C
and unpublished data). Cells at the immature B cell stage
are unable to mount a proliferative response after BCR
stimulation (45). This is consistent with the elevated num-
bers of immature B cells observed in the spleen (Fig. 4 B).
Alternatively, Lnk may be required by the BCR to trans-
mit a signal leading to proliferation. Further experiments
are underway to examine these issues. Together, these re-
sults indicate that the B lineage cells derived from Lnk / 
mice maintain growth characteristics that are typical of im-
mature populations. The B cell phenotype that we ob-
served is similar to the one identified by Takaki et al. (22).
However, in contrast with this group, we do not detect a
striking difference between wild-type and Lnk-deficient
mice in the mature B220hiIgM  population recirculating in
the bone marrow from the periphery. Therefore, in our
hands, the absence of the Lnk protein does not prevent the
recirculation of mature B cells into the bone marrow com-
partment, but does lead to an accumulation of phenotypi-
cally immature B cells.
Lnk /  Cells Exhibit Increased Proliferative Responses to Dif-
ferent Cytokines. The results of the clonogenic and B cell
proliferation assays suggest that Lnk may play an important
role in regulating myeloid and B cell progenitor prolifera-
tion. SCF, in combination with other growth factors, such
as IL-3, stimulates the proliferation of most hematopoietic
progenitors and mature cells (46). Therefore, we examined
the growth response of other hematopoietic cells derived
from wild-type and Lnk /  mice to various mitogenic stim-
uli. We first analyzed the response of primary bone marrow
and splenic cells from wild-type and Lnk /  mice to various
concentrations of SCF, IL-3, or a combination of both fac-
tors. No difference in proliferation was detected between
wild-type and Lnk /  bone marrow cells with SCF or IL-3
alone (Fig. 6 A, left and middle). The addition of SCF to
bone marrow cultures stimulated with IL-3 induced an in-
creased expansion of Lnk /  cells that was not seen in wild-
type cells (Fig. 6 A, right). A similar result was observed
when scoring the number of progenitor colonies formed in
the presence of SCF and different concentrations of IL-3
from Lnk /  mice (unpublished data). However, primary
Lnk /  splenocytes exhibited an enhanced sensitivity to ei-
ther SCF or IL-3 alone relative to wild-type cells (Fig. 6 B).
This hypersensitive proliferation of Lnk /  cells was more
pronounced in cultures stimulated with both SCF and IL-3
(Fig. 6 B). To pursue the effects of Lnk disruption in mito-
genic signals, we examined the growth properties of wild-
type and Lnk /  BMMCs in response to SCF and IL-3.
These cells provide a model system to study the effects of
these cytokines on cell proliferation and survival in a ho-
mogenous population. The mitogenic effects of SCF and
IL-3 were characterized by determining dose-dependent
DNA synthesis on SCF or IL-3 stimulation. Inactivation of
Lnk resulted in increased incorporation rates of [3H]thymi-
dine upon treatment of BMMCs with SCF (Fig. 6 C).
However, no consistent difference was found between
wild-type and Lnk-deficient BMMCs stimulated with IL-3
(Fig. 6 C). These observations suggest that Lnk negatively
regulates the proliferative response to growth factors in he-
matopoietic cells of different origin and demonstrate that
SCF alone or in synergy with IL-3 can induce a hypersensi-
tive proliferative response in vitro in Lnk / -derived cells.
Figure 5. Functional analysis of
Lnk /  B cells. (A) Bone marrow
sorted pro-B cells from wild-type
and  Lnk-deficient mice were
cultured with the indicated con-
centration of IL-7 and prolifera-
tion was measured at day 4 by
[3H]thymidine incorporation.
The values are the mean counts
per minute ( SD) of triplicate
determinations. Significance was
determined by Student’s t test:
***, P   0.001; **, P   0.005; *,
P   0.02. (B and C) Splenic B
cells were cultured with the indicated stimuli and proliferation was measured at day 6 (B) or day 4 (C) by [3H]thymidine incorporation. The values are
the mean counts per minute ( SD) of triplicate determinations. All graphs are representative of independent experiments repeated three to five times.
For each experiment, two mice per genotype were used.1607 Velazquez et al.
Lnk /  Cells Show Defects in SCF and IL-3 Signaling.
To assess the role of Lnk in the SCF and IL-3 pathways, we
used BMMC from wild-type and Lnk-deficient mice.
These cells express both Kit, the receptor for SCF, and IL-
3R chains, and their responses to IL-3 and SCF have been
well characterized (47, 48). Cells from both Lnk-deficient
and wild-type mice were starved for 12 h and then treated
for 10 min with IL-3. Both types of cells showed a similar
activation of the IL-3R  chain after IL-3 stimulation as
judged by antiphosphotyrosine blotting (Fig. 7 A). We
next examined the kinetics and extent of MAPK and Akt
activation on IL-3 stimulation of BMMCs. Cells were
starved and stimulated at different times with IL-3. No dif-
ferences in the activation of Akt were detected between
wild-type and Lnk /  BMMCs (Fig. 7 A). However, the
analysis of MAPK activation showed that the kinetics of
ERK1/2 were altered, such that the peak activation of
ERK1/2 was slightly delayed in Lnk /  BMMCs (Fig. 7, A
and B). We next analyzed the response of BMMCs to SCF
stimulation. Cells from wild-type and Lnk mutant mice
showed a similar activation of Kit and phosphorylation of
whole cell lysates (Fig. 7 C). To determine if a difference in
the extent of MAPK activation might be responsible for
the increased DNA synthesis rates observed in mutant cells
(Fig. 6 C), we analyzed the duration of MAPK activation
upon SCF stimulation. BMMCs from Lnk /  mice dis-
played a higher level of phospho-ERK1/2 (1.5–4-fold),
which decreased with a slower kinetics compared with
wild-type BMMCs cells (Fig. 7, C and D). Together, these
results suggest that Lnk negatively regulates signaling path-
ways downstream of both the IL-3R  and Kit receptors
that are implicated in cell proliferation.
Lnk Expression Is Regulated during Hematopoiesis. Lnk is
reportedly expressed throughout thymocyte development
and at high levels in B220  splenocytes (20). However, the
increased number of clonogenic progenitors observed in
Lnk /  mice suggests that Lnk expression may be regulated
during hematopoietic differentiation. To assess Lnk expres-
sion during hematopoiesis, a hierarchy blot was hybridized
with a radiolabeled Lnk cDNA probe including the termi-
nal 3  untranslated sequence (Fig. 8 A) and densitometric
analysis was performed. Hybridization of the Lnk probe
was strong in tripotent and unipotent precursors cells of
megakaryocyte and myeloid lineages, as well as in mature
megakaryocytes and macrophages, moderate in pentapo-
tent and unipotent precursors cells of the erythroid lineage
(BFU-E and CFU-E), and low in tetrapotent cells and
other terminally mature cells (erythrocytes, neutrophils,
mast, B and T cells).
To further characterize Lnk, we analyzed its expression
in different organs. Lnk was highly expressed in some non-
hematopoietic organs examined such as testis, brain, and
muscle (Fig. 8 B). Interestingly, although Lnk expression is
high in the bone marrow and lymph nodes, only low levels
of Lnk RNA were detected in the spleen (Fig. 8 B), par-
tially due to Lnk being weakly expressed in the mature cells
of which the spleen is primarily composed. All slot blots
were hybridized with a probe for L32, a constitutively ex-
pressed housekeeping transcript, to verify equal loading of
all cDNAs (Fig. 8 C). The specificity of the Lnk probe was
also confirmed by hybridization of a Northern blot. The
same Lnk transcripts detected in wild-type and heterozy-
gous cells with an NH2-terminal Lnk cDNA probe (Fig. 1
D) were observed with this 3  Lnk probe (Fig. 8 C). These
data demonstrate that Lnk is regulated in the hematopoietic
compartment, and is most abundantly expressed in hemato-
poietic precursors.
Discussion
Lnk-deficient mice display an abnormal accumulation of
erythroid cells, megakaryocytes, and B lymphocytes in the
different hematopoietic compartments, indicating a defect
in lymphoid and myeloid homeostasis. One of the most
Figure 6. Effect of Lnk disruption
on cell proliferation in hematopoi-
etic cells. Total bone marrow (A) or
splenic cells (B) from wild-type and
Lnk /  mice were cultured with the
indicated growth factors and prolif-
eration was measured at day 4 (A)
and day 6 (B) by an MTT assay. The
values represent the mean ( SD) of
triplicate determinations. (C) BMMCs
from wild-type and Lnk /  mice
were cultured with the indicated
concentrations of SCF or IL-3 for
28 h and proliferation was measured
as [3H]thymidine incorporation.
The values are the mean counts per
minute ( SD) of triplicate determi-
nations. All graphs are representative
of two independent experiments, each
done with two mice per genotype.1608 Role of Lnk in Hematopoietic Cells
striking features of Lnk-deficient mice is a profound sple-
nomegaly with excessive fibrosis and EMH. Morphologi-
cally, the abnormal expansion of B lymphocytes and eryth-
rocytes causes considerable change in the architecture of
the spleen, whereas the accumulation of a large number of
megakaryocytes may be responsible for the extensive fibro-
sis observed. This phenotype resembles human myelopro-
liferative disorders that are characterized by abnormal pro-
liferation of more than one hematopoietic cell lineage (49):
the myeloid lineage in chronic myelogenous leukemia
(CML); the erythrocytic and megakaryocytic lineages in
polycythemia vera; and megakaryocytic cells in essential
thrombocythemia and primary myelofibrosis. With the ex-
ception of CML, the molecular mechanisms responsible for
the clonal proliferation in these disorders are unknown.
Our results indicate that ablation of Lnk expression causes a
dysregulation of hematopoiesis reminiscent of these dis-
eases. Lnk-deficient mice exhibit amplification of both the
erythroid lineage (specifically in spleen) and the megakary-
ocytic lineage, enhanced sensitivity to several cytokines,
and abnormal responses to IL-3 and SCF. Interestingly,
transgenic mice expressing activated forms of the IL-3R 
chain display a chronic myeloproliferative disorder and an
acute leukemia-like syndrome (50, 51). Moreover, it has
been shown that the synergistic action of cytokines, such as
SCF, IL-3, IL-7, and EPO, provides a growth advantage to
multipotent progenitors and increases the frequency of my-
eloid, lymphoid, and erythroid progenitor cells (45, 52,
53). Indeed, preliminary analysis of erythroid progenitor
colony growth in the presence of IL-3 and different con-
centrations of EPO, showed a hypersensitive pattern of
growth in Lnk /  cells (unpublished data). Therefore, it is
possible that in the Lnk mutant mice, multiple cytokines
are able to stimulate or continuously sensitize multipotent
progenitors via synergistic combinations of growth factors,
such as SCF, IL-3, and other cytokines.
One important question deals with the regulation of Lnk
expression. This is particularly interesting because (1) Lnk
expression is first detected in 11.5-d embryos, at a stage in
which definitive hematopoiesis within the fetal liver is es-
tablished (unpublished data; reference 54); (2) its expression
is higher in hematopoietic precursors than in mature cells;
(3) the Lnk mutant phenotype is already visible in newborn
mice; and (4) Lnk /  mice display a phenotype intermedi-
ate between wild-type and mutant mice. These data sug-
gest that Lnk expression and function are tightly regulated
Figure 7. Analysis of IL-3 and SCF signaling pathways in Lnk-deficient BMMCs. (A and B) BMMCs from wild-type ( / ) and Lnk mutant ( / )
mice were stimulated with 100 ng/ml IL-3 for 10 min or for the indicated times. IL-3R  chain was immunoprecipitated from wild-type and Lnk / 
BMMCs lysates and analyzed with anti-Ptyr and anti–IL-3R  antibodies. Whole-cell lysates were subjected to Western blot analysis with anti–phospho-
Akt and anti-phospho-ERK1/2 antibodies. Anti-ERK1/2 antibodies were used to show equal loading. Normalized densitometric analysis of ERK phos-
phorylation is shown in B. (solid line) Wild-type; (dashed line) Lnk / . (C and D) Total BMMCs lysates were stimulated with 100 ng/ml SCF for the in-
dicated times and then subjected to Western blot analysis with anti-Ptyr, anti-Kit, and anti–phospho-ERK1/2 antibodies. Anti-ERK1/2 antibodies were
used to show similar loading. Normalized densitometric analysis of ERK phosphorylation is shown in D. (solid line) Wild-type; (dashed line) Lnk / . All
data are representative of four independent experiments. Each experiment was done with cells isolated from two mice per genotype.1609 Velazquez et al.
during hematopoiesis. It is possible that the high levels of
Lnk expression at later stages of hematopoiesis are impor-
tant for attenuating cell proliferation and inducing the ter-
minal stages of cell differentiation. This possibility is con-
sistent with the phenotype of the Lnk-deficient mice,
particularly the predominance of more immature cells in
peripheral sites. In this regard, it was surprising to observe
IL-7–responsive cells in the spleen of Lnk /  animals. It is
also possible that hematopoietic progenitors that migrate
out of the bone marrow retain a proliferative capacity and
cytokine sensitivity that would normally be controlled
through the induction of Lnk expression. The increase in
progenitor cell numbers from the Lnk mutant mice was as-
sociated with an increase in the number of cells within each
colony. This increase could be due to the capacity of these
cells to undergo more rounds of proliferation or to survive
for longer. Our data with Lnk-deficient cells suggest that
Lnk mainly exerts an effect on proliferation. In any case, it
is possible that Lnk expression is increased before differen-
tiation, thereby limiting colony size. Furthermore, it is evi-
dent that terminal differentiation can occur in Lnk mutant
cells, demonstrating that Lnk is not essential for this func-
tion, but rather serves a regulatory role.
The phenotypes observed in Lnk-deficient mice exhibit
several similarities with the phenotypes of mice deficient
for other molecules involved in the regulation of hemato-
poietic signaling such as p62dok, SHIP, SHP-1, and SOCS3
(17, 55–57). For example, BMMCs derived from SHP-1 / 
mice exhibit an augmented and prolonged activation of
ERK-1 in response to SCF compared with that observed in
Lnk /  mice (58). These parallels suggest that Lnk may also
function as a negative regulator of tyrosine kinase signaling
in hematopoietic cells. The mechanism by which the Lnk
family members influence growth factor and cytokine sig-
naling is hypothesized to be through their ability to posi-
tively or negatively regulate the JAK/STAT and/or the
Ras/MAPK pathways, based on overexpression studies of
SH2-B and APS (27, 32, 34, 35). In this regard, we have
not detected an effect of Lnk ablation on the activation of
JAK2 in BMMCs stimulated with IL-3 (unpublished data).
However, we have not yet examined the activation of the
JAK/STAT pathway in other cytokine-stimulated progeni-
tors. Experiments are in progress to analyze this pathway in
more detail. Our results with Lnk /  cells demonstrate that
Lnk can modulate the kinetics of activation of Ras/MAPK,
correlating with altered proliferation. Furthermore, Lnk
appears important in modulating the cellular response to
distinct growth factors (IL-3, IL-7, or SCF). A recent re-
port has demonstrated that MAPK activation is required for
the pBCR to signal proliferation of pre-B cells in low con-
centrations of IL-7 (39). It is possible that the elevated pro-
liferation of Lnk /  pre-B cells observed in these condi-
tions (Fig. 5 A) is due to an inability to properly regulate
ERK activation in the absence of Lnk expression. Identifi-
cation of Lnk-interacting proteins may provide insight into
how Lnk achieves its negative effect on cellular signaling,
and preliminary data indicate that the p85 subunit of PI3K
can associate with Lnk in B cells (unpublished data).
It was surprising to detect high levels of Lnk in nonhe-
matopoietic tissues such as testis, brain, and muscle because
the Lnk /  phenotype appears to exclusively affect the he-
matopoietic system. This is likely explained by the fact that
SH2B and APS are highly expressed in nonhematopoietic
tissues and therefore could compensate for the absence of
Lnk in other organs. APS is also highly expressed in the he-
matopoietic system, but mainly present in mature B cell
lines (23, 31, 32). This suggests that APS functions in ma-
ture cells where Lnk expression is very low and therefore
could explain the absence of a Lnk phenotype in terminally
mature cells. Thus, it will be important to analyze the phe-
notypes of mice genetically deficient in other Lnk family
members, separately or in combination, to establish the bi-
ological specificity of these adaptor proteins.
In conclusion, our results indicate that Lnk is an impor-
tant regulator of cytokine signaling during hematopoiesis.
Figure 8. Lnk expression during hematopoiesis. (A and B) A slot blot
containing either independent amplified cDNA samples from hematopoi-
etic cells ranging from pentapotent precursors to terminally maturing cells
in erythroid, myeloid, and lymphoid lineages (A) or different organs (B)
was hybridized with a 3  radiolabeled probe for Lnk. Radioactivity was
quantified with a Phosphorimager (Bio-Rad Laboratories), and the results
from A are shown in a hierarchy tree scheme: (black circles) high ex-
pression; (gray circles) moderate expression; (white circles) low expression.
The ghosted circle represents a committed mast cell precursor stage, not
actually sampled. E, erythroid; Meg, megakaryocyte; Mac or Mc, mono-
cyte/macrophage; N, neutrophil; Mast or Mst, mast cell; B, B cells; T, T
cells; BFU-E, precursors of large erythroid-only 6–8-d colonies; CFU-E,
precursors of small erythroid 2-d colonies; p, precursors of 7-d colonies;
pentapotent (E/Meg/Mac/N/Mst), tetrapotent (E/Meg/Mac/N), tripo-
tent (E/Meg/Mac), and bipotent (E/Meg) precursor cells; 3T3, NIH3T3
fibroblasts; S17, stromal cell line; sc, stem cell; BM, bone marrow; LN,
lymph node. (C) The same slot blots used in A and B were hybridized
with the L32 probe to confirm equal loading. HC, hematopoietic cells;
O, organs, same order as shown in A and B, respectively. A similar
Northern blot as the one used in Fig. 1 D vas hybridized vith the 3  Lnk
probe used in A and B to confirm specificity.1610 Role of Lnk in Hematopoietic Cells
Because of its role in maintaining homeostasis, Lnk /  mice
provide a powerful model in which to pursue Lnk function
in hematopoietic progenitor and mature cells. Future studies
with cells derived from these mice should contribute to the
understanding of the molecular mechanisms by which sig-
naling thresholds control hematopoietic homeostasis.
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